Executive Director, IQVIA Institute for Human Data Science
The biopharmaceutical sector is underpinned by a unique ecosystem that combines public funding for basic research, university-led translational science, technology transfers, venture capital funding, partnerships with larger companies, and a relatively transparent and responsive regulatory system.
Despite disruption from the COVID-19 pandemic still in full swing, life sciences innovation activity remained undeterred, a recent report from the IQVIA Institute for Human Data Science finds—outlining the key factors driving record-breaking growth.
